Assembly Biosciences reports the initiation of dosing in a Phase 1b clinical trial to evaluate ABI-M201 (M201) in patients with mildly to moderately active ulcerative colitis (UC).
M201 is Assembly’s first investigational oral live biotherapeutic product (LBP) to enter into clinical development, as part of its gastrointestinal (GI) focused collaboration with Allergan.
M201 is comprised of a rationally designed consortium of commensal bacteria that were selected based on ability to modulate ulcerative colitis-relevant cellular mechanisms in human cell-based assays and animal models. M201 is orally administered utilizing Assembly’s Gemicel® capsule-in-capsule delivery system, designed for targeted delivery into the GI tract. more